Quick Answer
Editas Medicine, Inc. reported Operating Income of -$160.01 million for fiscal year 2025.
Editas Medicine, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$160.01M | +36.3% |
| 2024 | -$251.15M | -48.5% |
| 2023 | -$169.18M | +25.1% |
| 2022 | -$225.95M | -17.0% |
| 2021 | -$193.15M | -43.2% |
| 2020 | -$134.84M | +4.3% |
| 2019 | -$140.92M | -23.9% |
| 2018 | -$113.73M | +5.2% |
| 2017 | -$119.93M | -23.4% |
| 2016 | -$97.19M | -175.2% |
| 2015 | -$35.31M | -177.5% |
| 2014 | -$12.72M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$24.55M | +62.6% | +52.4% |
| June 30, 2025 | -$51.54M | +28.3% | +32.3% |
| March 31, 2025 | -$76.16M | -13.7% | -16.0% |
| September 30, 2024 | -$65.67M | -30.9% | +8.7% |
| June 30, 2024 | -$71.90M | -63.1% | -7.3% |
| March 31, 2024 | -$66.99M | -31.5% | -33.5% |
| September 30, 2023 | -$50.16M | +12.8% | -13.8% |
| June 30, 2023 | -$44.09M | +18.7% | +13.5% |
- Editas Medicine, Inc. showed an increase of +36.3% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, Editas Medicine, Inc.’s operating income has declined by 1157.6% (from -$12.72 million to -$160.01 million).
- The most recent figure is from Editas Medicine, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: